Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsidiary PLIVA d.d announced that PLIVA has received final approval ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE